With a tumor harboring both 3+ and 0/1+ HER2 tumor cells, HER2-directed therapy may not work up front or may diminish as HER2-negative tumor cells outgrow HER2-positive tumor cells due to trastuzumab’s selective pressure in HER2 heterogenous tumors over time. Here, ERBB2 is linked to neoplasm.